title: Monitoring of circadian rhythms of heart rate, locomotor activity, and temperature for diagnosis and evaluation of response to treatment in an animal model of depression.
abstract: Depressive disorders affect approximately 5% of the population in developed countries each year. Current antidepressant treatment usually requires several weeks to obtain response or remission and is only effective in about half of depressed patients. Objective diagnostic tools and detection of symptom relief by physiological biomarkers may assist in the clinical decision-making process regarding the selection, replacing, and augmenting of antidepressants. Furthermore, such biomarkers may enable early prediction of the appropriateness of a specific antidepressant for a particular patient. Here, we examined a new non-invasive method for objective diagnosis of depressive-like behavior and for the purpose of predicting antidepressant (paroxetine and desipramine) treatment effectiveness. This method employed a genetic rat model of depression and mathematical analysis of physiological parameters, of circadian rhythms of heart rate, locomotor activity, and temperature for diagnosis and evaluation of response to treatment in an animal model of depression. By utilizing this method, we were able to discern, in a rat model, between depressive and non-depressive individuals and to predict beneficial response to the antidepressants. Mathematical analysis of physiological parameters such as heart rate, locomotor activity, and temperature circadian rhythms can be used for objective diagnosis of depressive-like behavior and for early prediction of response to antidepressant treatment.
authors.affiliation: Leslie Susan Gonda Multidisciplinary Brain Research Center, Bar-Ilan University, Ramat-Gan, 52900, Israel.
authors.forename: Alexander
authors.initials: A
authors.lastname: Friedman
authors.forename: Alena
authors.initials: A
authors.lastname: Shaldubina
authors.forename: Yakov
authors.initials: Y
authors.lastname: Flaumenhaft
authors.forename: Abraham
authors.initials: A
authors.lastname: Weizman
authors.forename: Gal
authors.initials: G
authors.lastname: Yadid
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D001831:Body Temperature / Q000187:drug effects / Q000502:physiology*; D002940:Circadian Rhythm / Q000502:physiology*; D003863:Depression / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology*; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D008297:Male; D023421:Models, Animal; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology*; D009483:Neuropsychological Tests; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000928:Antidepressive Agents
references.citation: Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H474-80
references.pmid: 17993598
references.citation: Psychosom Med. 2008 Jul;70(6):628-36
references.pmid: 18606724
references.citation: Appl Psychophysiol Biofeedback. 2007 Mar;32(1):19-30
references.pmid: 17333315
references.citation: J Clin Psychiatry. 2008 Sep;69(9):1404-15
references.pmid: 19193341
references.citation: Arch Gen Psychiatry. 2006 Nov;63(11):1217-23
references.pmid: 17088502
references.citation: Psychosomatics. 2004 Mar-Apr;45(2):129-34
references.pmid: 15016926
references.citation: Conf Proc IEEE Eng Med Biol Soc. 2005;2005:1216-9
references.pmid: 17282412
references.citation: J Affect Disord. 2010 Dec;127(1-3):266-73
references.pmid: 20538342
references.citation: Nutr Neurosci. 2003 Jun;6(3):169-75
references.pmid: 12793521
references.citation: Physiol Behav. 2003 Apr;78(4-5):703-10
references.pmid: 12782226
references.citation: Curr Drug Targets. 2009 Nov;10(11):1096-108
references.pmid: 19702553
references.citation: J Psychosom Res. 2004 Jan;56(1):89-94
references.pmid: 14987969
references.citation: Neurosci Biobehav Rev. 2005;29(4-5):739-59
references.pmid: 15925699
references.citation: Eur J Heart Fail. 2002 Dec;4(6):737-43
references.pmid: 12453544
references.citation: J Psychiatr Res. 2010 Nov;44(15):1043-51
references.pmid: 20537350
references.citation: Annu Rev Public Health. 2008;29:115-29
references.pmid: 18348707
references.citation: Auton Neurosci. 2010 Aug 25;156(1-2):117-23
references.pmid: 20447874
references.citation: J Clin Psychiatry. 2002 Jun;63(6):534-5; author reply 535-6
references.pmid: 12088168
references.citation: Behav Genet. 1995 Mar;25(2):179-85
references.pmid: 7733858
references.citation: Biopsychosoc Med. 2008 Jun 30;2:12
references.pmid: 18590531
references.citation: Curr Drug Targets. 2006 Feb;7(2):165-75
references.pmid: 16475958
references.citation: J Mol Neurosci. 2009 Sep;39(1-2):256-61
references.pmid: 19219568
references.citation: Arch Gen Psychiatry. 2005 Jun;62(6):593-602
references.pmid: 15939837
references.citation: Circulation. 2008 May 6;117(18):2407-23
references.pmid: 18427125
references.citation: Psychol Med. 2011 Apr;41(4):873-86
references.pmid: 20553636
references.citation: J Psychopharmacol. 1994 Jan;8(4):238-49
references.pmid: 22298630
references.citation: Anal Sci. 2003 Jan;19(1):139-46
references.pmid: 12558038
references.citation: J Gerontol A Biol Sci Med Sci. 2008 Dec;63(12):1410-5
references.pmid: 19126857
references.citation: Neuropharmacology. 2005 Jan;48(1):34-42
references.pmid: 15617725